Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etidaligide - Valerio Therapeutics

Drug Profile

Etidaligide - Valerio Therapeutics

Alternative Names: AsiDNA; Dbait; Dbait32H; DNA bait; DNA repair therapeutic - Valerio Therapeutics; DSB bait; DT-01; DT1

Latest Information Update: 19 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DNA Therapeutics
  • Developer Curie Institute; Gustave Roussy; Valerio Therapeutics
  • Class Antineoplastics; DNA; Immunotherapies
  • Mechanism of Action DNA repair enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer; Glioma; Malignant melanoma; Ovarian cancer; Prostate cancer
  • Phase I Solid tumours

Most Recent Events

  • 20 Oct 2023 Onxeo suspends the phase I/II REVOCAN trial in Ovarian cancer (Second-line therapy or greater) in France (Parenteral) (NCT04826198)
  • 20 Oct 2023 Efficacy and adverse events data from a phase I/II REVOCAN trial in Ovarian cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 20 Feb 2023 Phase-I/II clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IV, Infusion) (NCT05700669)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top